Effects of piperine, cinnamic acid and gallic acid on rosuvastatin pharmacokinetics in rats

Phytotherapy Research

Volumn 27, Issue 10, 2013, Pages 1548-1556

  Basu, Sudipta ^a   Jana, Snehasis ^a   Patel, Vandana B ^b   Patel, Hitesh ^a  

^a Sai Advantium Pharma Ltd   (India)

^b Gujarat Technological University   (India)

Author keywords

area under the curve; breast cancer resistance protein; cinnamic acid; gallic acid; piperine; rosuvastatin

Indexed keywords

CINNAMIC ACID; GALLIC ACID; PIPERINE; ROSUVASTATIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG TRANSPORT; HUMAN; HUMAN CELL; MEAN RESIDENCE TIME; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

RATTUS; RICE STRIPE VIRUS;

AREA UNDER THE CURVE; BREAST CANCER RESISTANCE PROTEIN; CINNAMIC ACID; GALLIC ACID; PIPERINE; ROSUVASTATIN;

ADMINISTRATION, ORAL; ALKALOIDS; ANIMALS; AREA UNDER CURVE; BENZODIOXOLES; BILE; CINNAMATES; DOGS; DRUG INTERACTIONS; FLUOROBENZENES; GALLIC ACID; MADIN DARBY CANINE KIDNEY CELLS; MALE; PIPERIDINES; POLYUNSATURATED ALKAMIDES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES;

EID: 84885624400     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4894     Document Type: Article

References (53)

1. Atal CK, Zutshi U, Rao PG,. 1981. Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. J Ethnopharmacol 4: 229-232. (Pubitemid 11014202)
2. Atal CK, Dubey RK, Singh J,. 1985. Biochemical basis of enhanced drug bioavailability by PIP: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 232: 258-262. (Pubitemid 15193683)
3. Bano G, Amla V, Raina RK, et al,. 1987. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med 53: 568-569. (Pubitemid 18004300)
4. Bano G, Raina RK, Zutshi U, et al,. 1991. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 41: 615-617.
5. Bergman E, Forsell P, Tevell A, et al,. 2006. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur J Pharm Sci 29: 205-214. (Pubitemid 44602407)
6. Bergman E, Lundahl A, Fridblom P, et al,. 2009. Enterohepatic disposition of rosuvastatin in pigs and the impact of concomitant dosing with cyclosporine and gemfibrozil. Drug Metab Dispos 37: 2349-2358.
7. Bhardwaj RK, Glaeser H, Becquemont L, et al,. 2002. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302: 645-650. (Pubitemid 34787231)
8. Burger H, van Tol H, Boersma AW, et al,. 2004. Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood 104: 2940-2942. (Pubitemid 39434984)
9. Carswell CI, Plosker GL, Jarvis B,. 2002. Rosuvastatin. Drugs 62: 2075-2085. (Pubitemid 35204040)
10. Cooper KJ, Martin PD, Dane AL, et al,. 2002. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 58: 527-531. (Pubitemid 35435506)
11. Cooper KJ, Martin PD, Dane AL, et al,. 2003a. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 55: 94-99. (Pubitemid 36110844)
12. Cooper KJ, Martin PD, Dane AL, et al,. 2003b. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 59: 51-56. (Pubitemid 36702759)
13. Cooper KJ, Martin PD, Dane AL, et al,. 2003c. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 73: 322-329. (Pubitemid 36403592)
14. Feng HP, Huang CL, Zhang LT, Li RF,. 2004. Pharmacokinetics and bioavailability of cinnamic acid in mice. J China Pharm Univ 35: 328-330.
15. Foti S, Wholstrom JL,. 2008. The role of dietary supplements in cytochrome P450-mediated drug interactions. Bol Latinoam Caribe Plant Med Aromaticas 7: 66-84.
16. Fuchikami H, Satoh H, Tsujimoto M, et al,. 2006. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 34: 577-582.
17. Greenblatt DJ,. 2009. Analysis of drug interactions involving fruit beverages and organic anion- transporting polypeptides. J Clin Pharmacol 49: 1403-1407.
18. Harris RZ, Jang GR, Tsunoda S,. 2003. Dietary effects on drug metabolism and transport. Clin Pharmacokinet 42: 1071-1088. (Pubitemid 37357646)
19. Havsteen BH,. 2002. The biochemistry and medical significance of the flavonoids. Pharmacol Ther 96: 67-202. (Pubitemid 35356564)
20. van Herwaarden AE, Schinkel AH,. 2006. The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends Pharmacol Sci 27: 10-16. (Pubitemid 43063119)
21. Hirofumi T, Hiroki S, Satoko H, Hisakazu O, Yasufumi S,. 2010. Inhibitory Effects of Herbal Extracts on Breast Cancer Resistance Protein (BCRP) and Structure-Inhibitory Potency Relationship of Isoflavonoids. Drug Metab Pharmacokinet 25: 170-179.
22. Ho RH, Kim RB,. 2005. Transporters and drug therapy: Implications for drug disposition and disease. Clin Pharmacol Ther 78: 260-277. (Pubitemid 41254111)
23. Ho RH, Tirona RG, Leake BF, et al,. 2006. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130: 1793-1806.
24. Huang L, Wang Y, Grimm S,. 2006. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 34: 738-742.
25. Ioannides C,. 2002. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 32: 451-478. (Pubitemid 34743619)
26. Jackson GD, Dai Y, Sewell WA,. 2000. Bile mediates intestinal pathology in endotoxemia in rats. Infect Immun 68: 4714-4719. (Pubitemid 30497745)
27. Jesky R, Hailong C,. 2011. Are herbal compounds the next frontier for alleviating learning and memory impairments? An integrative look at memory, dementia and the promising therapeutics of traditional chinese medicines. Phytother Res 25 (8): 1105-1118.
28. Jonker JW, Smit JW, Brinkhuis RF, et al,. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92: 1651-1656.
29. Jonker JW, Merino G, Musters S, et al,. 2005. The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat Med 11: 127-129. (Pubitemid 40321346)
30. Kang MJ, Cho JY, Shim BH, Kim DK, Lee J,. 2009. Bioavailability enhancing activities of natural compounds from medicinal plants. J Med Plants Res 13: 1204-1211.
31. Khajuria A, Zutshi U, Bedi KL,. 1998. Permeability characteristics of piperine on oral absorption-an active alkaloid from peppers and a bioavailability enhancer. Indian J Exp Biol 36: 46-50. (Pubitemid 28063097)
32. Kitamura S, Maeda K, Wang Y, Sugiyama Y,. 2008. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 36: 2014-2023.
33. Kruijtzer CM, Beijnen JH, Rosing H, Huinink WW, et al,. 2002. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. J Clin Oncol 20: 2943-2950. (Pubitemid 34728888)
34. Majumdar AM, Dhuley JN, Deshmukh VK, Naik SR,. 1999. Effect of Piperine Bioavailability of Oxyphenylbutazone in rats. Indian Drugs 36: 123-124.
35. Mao Q, Unadkat JD,. 2005. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7: E118-E133. (Pubitemid 41554295)
36. Martin PD, Kemp J, Dane AL, et al,. 2002. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 42: 1352-1357. (Pubitemid 35373605)
37. Martin PD, Warwick MJ, Dane AL, et al,. 2003a. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 25: 2822-2835. (Pubitemid 37510592)
38. Martin PD, Warwick MJ, Dane AL, et al,. 2003b. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 25: 2553-2563. (Pubitemid 37373930)
39. McTaggart F,. 2003. Comparative pharmacology of rosuvastatin. Atheroscler Suppl 4: 9-14. (Pubitemid 38234502)
40. Middleton E, Jr., Kandaswami C, Theoharides TC,. 2000. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 52: 673-751.
41. Navin P, Atal B, Bedi KL,. 2010. Bioenhancers: Revolutionary concept to market. J Ayur Intergrat Med 1: 96-99.
42. Patwardhan B, Mashelkar RA,. 2009. Traditional medicineinspired approaches to drug discovery and development: can Ayurveda show a way forward? Drug Discov Today 14: 804-811.
43. Schneck DW, Birmingham BK, Zalikowski JA, et al,. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75: 455-463. (Pubitemid 38534566)
44. Shobha G, Joseph T, Majeed M, et al,. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Plant Med 64: 353-356. (Pubitemid 28234275)
45. Simonson SG, Raza A, Martin PD, et al,. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76: 167-177. (Pubitemid 39013406)
46. Spelman K, Aldag R, Hamman A, et al,. 2011. Traditional herbal remedies that influence cell adhesion molecule activity. Phytother Res 25 (4): 473-483.
47. Tanaka Y, Slitt AL, Leazer TM, Maher JM, Klaassen CD,. 2005. Tissue distribution and hormonal regulation of the breast cancer resistance protein (Bcrp/Abcg2) in rats and mice. Biochem Biophys Res Commun 326: 181-187.
48. Thompson PD, Clarkson P, Karas RH,. 2003. Statin-associated myopathy. JAMA 289: 1681-1690. (Pubitemid 37430274)
49. Wang X, Wolkoff AW, Morris ME,. 2005. Flavonoids as a novel class of human organic anion- transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33: 1666-1672. (Pubitemid 41539965)
50. Zeng Y, Song JX, Shen XC,. 2012. Herbal remedies supply a novel prospect for the treatment of atherosclerosis: a review of current mechanism studies. Phytother Res 26 (2): 159-167.
51. Zhang S, Morris ME,. 2003. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304: 1258-1267. (Pubitemid 36254439)
52. Zhang S, Yang X, Morris ME,. 2004. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol 65: 1208-1216. (Pubitemid 38543491)
53. Zhang L, Reynolds KS, Zhao P, Huang S-M,. 2010. Drug interactions evaluation: An integrated part of risk assessment of therapeutics. Toxicol Appl Pharmacol 234 (2): 134-145.